# Prevest Denpro (NSE: PREVEST) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/PREVEST · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹472 Cr, it ranks 1820th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.

Its return on equity was 16.4% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹19 Cr (+2.7% year on year) and net profit ₹6 Cr (+13.2%), on a consolidated basis. Promoters held 73.60% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹472 Cr |
| ROE | 16.4% (FY26) |
| ROCE | 21.9% (FY26) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹19 Cr | +2.7% | ₹6 Cr | +13.2% | ₹4.85 |
| Q3 FY26 | ₹18 Cr | +23.5% | ₹5 Cr | +4.2% | ₹3.93 |
| Q2 FY26 | ₹19 Cr | +14.6% | ₹6 Cr | +14.9% | ₹4.62 |
| Q1 FY26 | ₹16 Cr | +18.0% | ₹4 Cr | +20.2% | ₹3.67 |
| Q4 FY25 | ₹18 Cr | +13.6% | ₹5 Cr | +7.8% | ₹4.28 |
| Q3 FY25 | ₹15 Cr | +9.8% | ₹5 Cr | +24.5% | ₹3.77 |
| Q2 FY25 | ₹16 Cr | +23.4% | ₹5 Cr | +32.4% | ₹4.01 |
| Q1 FY25 | ₹13 Cr | −0.2% | ₹4 Cr | −10.0% | ₹3.06 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹63 Cr | ₹18 Cr |
| FY24 | ₹56 Cr | ₹16 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 73.60%
- Foreign institutions: 0.65%
- Domestic institutions: 0.79%
- Non-institutions: 24.96%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Hemant Surgical](https://app.pivotnow.in/stock/HSIL) | — | ₹551 Cr | — | — |
| [HALEOS LABS](https://app.pivotnow.in/stock/HALEOSLABS) | ₹1,540.00 | ₹466 Cr | 26.9 | — |
| [Albert David](https://app.pivotnow.in/stock/ALBERTDAVD) | ₹795.00 | ₹454 Cr | — | — |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹905.20 | ₹399 Cr | 11.5 | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |

## Questions and answers

### What is the market cap of Prevest Denpro?

Prevest Denpro's market capitalisation is ₹472 Cr (₹472 Cr) at the 19 Oct 2026 close, ranking 1820th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Prevest Denpro?

Return on equity was 16.4% in FY26 and return on capital employed was 21.9% in FY26 (consolidated figures).

### Is Prevest Denpro a debt-free company?

Prevest Denpro is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Prevest Denpro's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Prevest Denpro reported revenue of ₹19 Cr, +2.7% year on year, and net profit of ₹6 Cr, +13.2% year on year.

### What is the shareholding pattern of Prevest Denpro?

As of 30 Jun 2026: promoters 73.60%, foreign institutions 0.65%, domestic institutions 0.79%, non-institutions 24.96%.

### Who are Prevest Denpro's competitors?

The listed Pharma & Healthcare companies closest to Prevest Denpro by market cap are Hemant Surgical, HALEOS LABS, Albert David, Asarfi Hospital, Jenburkt Pharma and Transchem.

### Is Prevest Denpro a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Prevest Denpro's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PREVEST against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.